{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:22Z","timestamp":1792718362051,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI142872"],"award-info":[{"award-number":["R01 AI142872"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI172938"],"award-info":[{"award-number":["R01 AI172938"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI151591"],"award-info":[{"award-number":["R21 AI151591"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24 AI106822"],"award-info":[{"award-number":["K24 AI106822"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jaci.2024.07.019","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:04:26Z","timestamp":1723010666000},"page":"1195-1203.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A\u00a0population-based cohort study"],"prefix":"10.1016","volume":"154","author":[{"given":"Serena Yun-Chen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Hawryluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko K.","family":"Oyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-4144","authenticated-orcid":false,"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.07.019_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","article-title":"What\u2019s new in topicals for atopic dermatitis?","volume":"23","author":"Kleinman","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","article-title":"Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis","volume":"9","author":"Boguniewicz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.07.019_bib4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2024.07.019_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/all.16265","article-title":"Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study","author":"Tsai","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.07.019_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2024.07.019_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.07.019_bib7","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.019_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the (black) box: a dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.07.019_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2024.07.019_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/pds.5586","article-title":"Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis","volume":"32","author":"Anand","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaci.2024.07.019_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.04.079","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on inflammatory skin diseases in patients with type 2 diabetes","author":"Ma","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cjca.2021.05.012","article-title":"Emulating a randomised controlled trial with observational data: an introduction to the target trial framework","volume":"37","author":"Kutcher","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jaci.2024.07.019_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.2019.21558","article-title":"Using propensity score methods to create target populations in observational clinical research","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2024.07.019_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaci.2024.07.019_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.07.019_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","article-title":"Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/bjd\/ljad229","article-title":"Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis","volume":"189","author":"Ertus","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Yoon","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2024.07.019_bib21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","article-title":"Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study","volume":"73","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2024.07.019_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am Heart J"},{"issue":"10246","key":"10.1016\/j.jaci.2024.07.019_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.07.019_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.019_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2024.01.004","article-title":"Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study","volume":"90","author":"Avallone","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"10290","key":"10.1016\/j.jaci.2024.07.019_bib29","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.07.019_bib30","first-page":"456","article-title":"JAK inhibitors in the treatment of myelofibrosis","volume":"20","author":"Levavi","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.jaci.2024.07.019_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","article-title":"Dupilumab provides sustained effectiveness on patient-reported outcomes and\u00a0favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry","volume":"91","author":"Zhang","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaci.2024.07.019_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2023.08.025","article-title":"Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: a US nationwide cohort study","volume":"90","author":"Schneeweiss","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.07.019_bib36","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2024.07.019_bib37","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924007760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924007760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:16:50Z","timestamp":1730809010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924007760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0091674924007760"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.019","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A\u00a0population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}